QuickStrip

04/13/2026

Rapid Dose Therapeutics is advancing the next phase of its Burlington facility expansion targeting global medical markets to strengthen pharmaceutical manufacturing capability, support future regulatory pathways, and expand the long-term strategic value of its QuickStrip™ platform.

This is more than a facility upgrade. It is a disciplined investment in infrastructure designed to support scale, flexibility, and future participation in regulated global medical markets.

Why this matters:
• Global prescription drug sales are forecast to reach approximately US$1.7 trillion by 2030.
• The global medical cannabis market is projected to reach approximately US$65.9 billion by 2030.
• As demand grows for compliant, non-combustible, patient-friendly delivery formats, manufacturing readiness becomes a strategic advantage.

https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-advances-pharmaceutical-manufacturing-expansion-with-burlington-facility-upgrades-targeting-global-medical-markets/

BURLINGTON, ON — April 13, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at i...

03/05/2026

Major Patent Milestone!

Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Secures Patent for QuickStrip™ Ni****ne Oral Film Targeting $38B Smoke-Free Ni****ne Market

Key Highlights for Investors:

• Massive Addressable Market: The global modern oral ni****ne market is projected to reach $38.89 Billion by 2033, growing at a 19% CAGR.

• Global IP Footprint: This grant follows our 2025 WIPO PCT filing, extending potential protection to up to 158 jurisdictions worldwide.

• Strategic Advantage: Partnered with Aavishkar Oral Strips, we are positioned to disrupt traditional ni****ne delivery with a discreet, smoke-free alternative.

• Ongoing Discussions: RDT remains engaged in commercial discussions with a major global ni****ne company, a relationship now backed by stronger IP.

Read the full press release here:
https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-secures-patent-for-quickstrip-ni****ne-oral-film-targeting-38b-smoke-free-ni****ne-market/

****neReplacement $DOSE $RDTCF

BURLINGTON, Ontario — March 5, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Ni****ne Bilayer Oral Film in partnership with...

02/23/2026

Rapid Dose Therapeutics advances cannabinoid research and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform. Independent studies, supported by grant funding, are exploring cannabinoids’ role in pain management and neuroprotection related to concussion and participation in contact sports, while a clinical arm is assessing CBD bioavailability vs traditional oral formats.

https://www.newsfilecorp.com/release/284877

$DOSE $RDTCF

Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. ...

02/18/2026

🚨 INVESTOR ALERT: Aegis Research sees $1.00 path for Rapid Dose Therapeutics Corp (CSE: $DOSE | OTCQB: $RDTCF). 80% bioavailability tech + 45% sales growth
Watch: https://youtu.be/nbX0dLxSllM

$DOSE $RDTCF

Overview of Rapid Dose Therapeutics (CSE: DOSE) (OTC: RDTCF) and its proprietary QuickStrip We are not Financial Advisers and Do Your Own Research. Aegis R...

11/20/2025

A new CEO.ca interview featuring Rapid Dose Therapeutics CEO Mark Upsdell (CSE: DOSE).

He discusses NicStrip™, RDT’s ni****ne oral thin-film format, current development activity, ongoing regulatory submissions, and the QuickStrip™ platform.

10/20/2025

RDT advances NicStrip(TM) commercialization with $1.8 million CAD extension

https://www.newsfilecorp.com/release/271072

****neAlternatives ****neMarket $DOSE

Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian...

08/05/2025

Rapid Dose Therapeutics Submits QuickStrip™ Ni****ne Product for Health Canada Approval

Innovative Oral Ni****ne Delivery Technology Targets Safer Alternative for Smokers

https://shorturl.at/REOZu

****neAlternative ****ne ****neInnovation

Innovative Oral Ni****ne Delivery Technology Targets Safer Alternative for Smokers Burlington, ON – August 4, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company focused on innovative drug delivery technologies, is pleased to announ...

07/31/2025

Rapid Dose Therapeutics and Eco Canadian Organic Inc. Initiate Health Canada Funded SUAP Harm Reduction Pilot Project on First Nations Using QuickStrip™ to Combat **te Crisis

https://shorturl.at/O4JX6

Burlington, Ontario – July 29, 2025– Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company, is proud to announce the launch of a new significant harm reduction initiative aimed at addressing the devastating opioid crisis gripping Canada’s ...

07/02/2025

In June, QuickStrip™ by Rapid Dose Therapeutics was featured in RecoverCann’s WGY6 campaign for Men’s Mental Health and PTSD Awareness Month—spotlighting wellness-oriented innovations

This visibility aligns with a major research milestone: QuickStrip™ is currently being studied in an NFL-funded clinical trial, led by researchers at the University of Regina and the University of Saskatchewan. The study is evaluating the pharmacokinetics of CBD when delivered through RDT’s QuickStrip™ compared to traditional oral formats. The strips are rectangular oral thin films infused with cannabis extract, which, when placed under the tongue, dissolve and release the cannabis extract into the mucus membranes of the mouth.

CEO.CA has issued a press release as part of its latest Inside the Boardroom series, featuring Rapid Dose Therapeutics.

You can read the full press release here:
https://lnkd.in/eh3t-HvG

05/27/2025

Patented Innovation in Ni****ne Delivery

Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Ni****ne Delivery Technology.

These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use.

https://rapid-dose.com/rapid-dose-therapeutics-and-aavishkar-oral-strips-file-two-key-patents-for-innovative-ni****ne-delivery-technology/

****neInnovation $DOSE

BURLINGTON, ON – May 26, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in pa...

11/11/2024

Today on this Remembrance Day, we commemorate and honor the courage, sacrifice, and resilience of those who have served and continue to serve.

Lest we forget.

10/14/2024

This Thanksgiving, we are grateful for our team members and all that they do. From our RDT family to yours, we wish you a !